Last reviewed · How we verify
Preop orphenadrine IV
Preop orphenadrine IV, marketed by AdventHealth, is an intravenous formulation currently available in the market with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique IV administration, which may offer a competitive edge in perioperative settings. However, the primary risk lies in the potential for generic competition post-patent expiry in 2028, which could significantly erode market share and revenue.
At a glance
| Generic name | Preop orphenadrine IV |
|---|---|
| Also known as | Norflex |
| Sponsor | AdventHealth |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery (PHASE4)
- Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preop orphenadrine IV CI brief — competitive landscape report
- Preop orphenadrine IV updates RSS · CI watch RSS
- AdventHealth portfolio CI